KP-1461

KP-1461
Clinical data

Drug class	Reverse transcriptase inhibitor
Legal status
Legal status	Investigational
Identifiers
CAS Number	815588-85-3
PubChem CID	51003457
DrugBank	05644
ChemSpider	32702166
UNII	3PEN569TJP
Chemical and physical data
Formula	C₁₆H₂₃N₄O₆
Molar mass	367.382 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O
InChI InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1 Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.^[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.^{[citation needed]}

KP-1461 is a prodrug of the active antiviral agent KP-1212.^[2]

References

^ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
^ "KP-1461". DrugBank. Canadian Institutes of Health Research.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Protease Inhibitors (PI)
(Discovery and development)

1^st generation	Amprenavir (APV)^‡ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV)^◊ Ritonavir (RTV)^# Saquinavir (SQV)^◊
2^nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)^◊ TMC-310911^§

Non-nucleoside (NNRTI)
(Discovery and development)

1^st generation	Efavirenz (EFV)^# Nevirapine (NVP)^# Delavirdine (DLV)^‡
2^nd generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide KP-1461^† Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

This page was last edited on 9 August 2023, at 16:13